7月8日,记者跟随“2026年活力中国调研行”主题采访活动走进张江创新药企业迈威生物,实地探访企业从基础靶点发现、前沿技术开发到临床转化落地的全链条创新体系。 据迈威生物董事长、首席执行官刘大涛介绍,作为扎根张江的创新生物药企,迈威生物始终以源头自主创新为核心竞争力,依托ADC药物研发平台、TCE双抗/三抗开发平台等自研技术平台,打通基础研究、应用开发、成果转化闭环,走出一条具备完全自主知识产权...
Source Link7月8日,记者跟随“2026年活力中国调研行”主题采访活动走进张江创新药企业迈威生物,实地探访企业从基础靶点发现、前沿技术开发到临床转化落地的全链条创新体系。 据迈威生物董事长、首席执行官刘大涛介绍,作为扎根张江的创新生物药企,迈威生物始终以源头自主创新为核心竞争力,依托ADC药物研发平台、TCE双抗/三抗开发平台等自研技术平台,打通基础研究、应用开发、成果转化闭环,走出一条具备完全自主知识产权...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.